By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
NovaBiotics is a company now pivoting to develop its antimicrobials to fight COVID and COVID-related bacterial infections, starting in the lungs. COVID is a virus, but infection with it often creates opportunities for other types of microbes to invade patients and overcome their natural defenses.
The company’s CEO, Deborah O’Neil, shares some surprising information about the way COVID has enlivened not only her company’s area of business, but also the antibiotics space industrywide. Antibiotics has quickly morphed from the sleepy area we were all talking about just a few months ago — dominated by antibiotic resistance and skittish investors — to an awakened space generating new interest and investment from VCs to Big Pharmas, with added help from regulators.